- Home
- JFB vs INMB Comparison
JFB vs INMB Comparison
Compare JFB & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFB
- INMB
- Stock Information
- Founded
- JFB 2014
- INMB 2015
- Country
- JFB United States
- INMB United States
- Employees
- JFB N/A
- INMB N/A
- Industry
- JFB
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- JFB
- INMB Health Care
- Exchange
- JFB NYSE
- INMB Nasdaq
- Market Cap
- JFB 68.6M
- INMB 68.9M
- IPO Year
- JFB 2025
- INMB 2019
- Fundamental
- Price
- JFB $7.69
- INMB $2.71
- Analyst Decision
- JFB
- INMB Buy
- Analyst Count
- JFB 0
- INMB 4
- Target Price
- JFB N/A
- INMB $9.53
- AVG Volume (30 Days)
- JFB 43.2K
- INMB 7.1M
- Earning Date
- JFB 08-11-2025
- INMB 08-04-2025
- Dividend Yield
- JFB N/A
- INMB N/A
- EPS Growth
- JFB N/A
- INMB N/A
- EPS
- JFB 0.00
- INMB N/A
- Revenue
- JFB $25,946,544.00
- INMB $50,000.00
- Revenue This Year
- JFB N/A
- INMB $203.60
- Revenue Next Year
- JFB N/A
- INMB $13,122.47
- P/E Ratio
- JFB $1,980.47
- INMB N/A
- Revenue Growth
- JFB N/A
- INMB N/A
- 52 Week Low
- JFB $3.39
- INMB $1.89
- 52 Week High
- JFB $10.46
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- JFB N/A
- INMB 37.72
- Support Level
- JFB N/A
- INMB $2.04
- Resistance Level
- JFB N/A
- INMB $3.07
- Average True Range (ATR)
- JFB 0.00
- INMB 0.23
- MACD
- JFB 0.00
- INMB 0.22
- Stochastic Oscillator
- JFB 0.00
- INMB 65.05
About JFB JFB CONSTRUCTION HOLDINGS
JFB Construction Holdings is a commercial and residential real estate construction and development company. It is engaged in retail corporate buildouts, multifamily community developments and luxury residential homes, with a focus on fostering long-term relationships with clients, partners, and communities. The company operates in three distinct business segments: Commercial Construction, Residential Construction, and Real Estate Development. Key revenue is generated from Commercial Construction: This segment includes all activities related to the construction of commercial properties such as office buildings, retail spaces, and industrial facilities.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.